Comparison

TGFBR1 Recombinant Protein

Item no. OPCD07393
Manufacturer AVIVA Systems Biology
Amount 10 ug
Category
Type Proteins Recombinant
Applications WB, SDS-PAGE
Specific against Human (Homo sapiens)
Host E.coli
Conjugate/Tag Unconjugated; HIS
Purity > 97%
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Alias AAT5;activin A receptor type II-like kinase,53kDa;activin A receptor type II-like protein kinase of 53kD;activin receptor-like kinase 5;ACVRLK4;ALK5;ALK-5;ESS1;LDS1;LDS1A;LDS2A;MSSE;mutant transforming growth factor beta receptor I;serine/threonine-protein kinase receptor R4;SKR4;tbetaR-I;TBR-i;TBRI;TGF-beta receptor type-1;TGF-beta type I receptor;TGFR-1;transforming growth factor beta receptor I;transforming growth factor-beta receptor type I.
Available
Manufacturer - Type
Protein
Manufacturer - Applications
Positive control|Sodium sodecyl sulfate - polyacrylamide gel electrophoresis|Western blot
Manufacturer - Category
Root Catalog/Products/Recombinant Proteins
Manufacturer - Conjugate / Tag
N-terminal His Tag
Molecular Weight
33kDa
Gene symbol
TGFBR1
Gene Fullname
transforming growth factor beta receptor 1
Protein size
Recombinant
Product format
Freeze-dried Powder. PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
Reconstitution and storage
2°C to 8°C|-80°C
Description of target
Transmembrane serine/threonine kinase forming with the TGF-beta type II serine/threonine kinase receptor, TGFBR2, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. For instance, TGFBR1 induces TRAF6 autoubiquitination which in turn results in MAP3K7 ubiquitination and activation to trigger apoptosis. Also regulates epithelial to mesenchymal transition through a SMAD-independent signaling pathway through PARD6A phosphorylation and activation.
Nucleotide accession_num
NM_001130916.2
Protein accession_num
NP_001124388.1
Protein name
TGF-beta receptor type-1
Formulation
20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
Concentration
200 ug/mL (prior to lyoph)

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 10 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close